Tellgen Corp (300642) Fair Value & Analysis
Healthcare · CN · Market cap 2.1B CNY
Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Strengths
Risks
Fair value as of: Aug 25, 2026
From 25 valuation models · updated 2 days ago
Share price +45.1% over the past month.
A solid business, but trading 750% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥2.54). The favourable scenario is already priced in.
- Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥1.34 to ¥2.54) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 25, 2026.
How to read this chart
60‑month range ¥10.31 – ¥45.44 · fair‑value band ¥1.34 – ¥2.54 · the ¥17.24 price screens above the ¥2.03 fair value. Dashed = 300-day average. As of Aug 25, 2026.
Analysis
Tellgen Corp (300642) currently trades at ¥17.24, while our model-based Fair Value estimate is ¥2.03, implying the stock looks roughly 88.2% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Tellgen Corp generated revenue of 372M CNY at a net margin of -0.7%. Revenue grew 10.3% year over year. It earns a return on equity of -0.4%. The balance sheet holds a net cash position of 212M CNY. Fundamentals as of Aug 25, 2026
Our scenario range runs from ¥1.34 (bear case) to ¥2.54 (bull case); at ¥17.24, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high and 39% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside, at -88%, 300642 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Asset-Based (¥5.88) versus Earnings-Based (¥0.1500). Highest evidence: Growth DCF (80).
Notify me when 300642 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation.
Full company description
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in 2003 and is based in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tellgen Corp reported revenue of ¥364M in FY2025 versus ¥655M in FY2021, a compound −13.7%/yr. Reported net income was ¥3.6M in FY2025, compounding −61.4%/yr from FY2021.
of which total revenue +18.6 pp · buybacks/dilution −3.8 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
300642 screens 88% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 363 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $327.70 | $186.28 | -43% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $50.37 | $38.44 | -24% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Siemens Healthineers AG SHL | €39.04 | €33.87 | -13% |
| DexCom, Inc DXCM | $90.80 | $38.95 | -57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | -14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | -39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | -2% |
Compare Tellgen Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Tellgen Corp (300642) overvalued or undervalued?
What is the fair value of 300642?
What is the quality score of 300642?
What is the revenue of Tellgen Corp (300642)?
What is the net profit margin of 300642?
Does Tellgen Corp pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Tellgen Corp in the live analysis
One click puts Tellgen Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.